Drugs & Targets FDA approves Fruzaqla for previously treated metastatic CRC November 10, 2023Vol.49 No.42
Drugs & Targets FDA approves neoadjuvant/ adjuvant Keytruda for resectable NSCLC October 20, 2023Vol.49 No.39
Drugs & Targets FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma October 20, 2023Vol.49 No.39
In Brief Julie Beitz named principal drug regulatory expert at Hyman, Phelps & McNamara October 13, 2023Vol.49 No.38
Drugs & Targets FDA approves encorafenib with binimetinib for metastatic NSCLC with a BRAF V600E mutation October 13, 2023Vol.49 No.38
Real-world Evidence Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study showsFDA says raw images enrich the data when used with clinician assessments October 06, 2023Vol.49 No.37By Matthew Bin Han Ong
